… A phase I study of perifosine, lenalidomide, and … , identifying another potential biomarker
for agents targeting the PI3K/… to bortezomib and dexamethasone with or without perifosine but …

… of cases of refractoriness to novel drugs was three. Four cases were lenalidomide (LEN) …
-330 in vivo, this combination exhibited significant anti-myeloma activity against MM cells in …

… immunomodulatory drugs (IMiDs) such as lenalidomide or … inhibiting activity displayed
promising anti-myeloma activity [80]. … perifosine combined with BTZ revealed increase cytotoxicity …

… paired with existing and novel agents to induce high clinical … Bortezomib with lenalidomide
and dexamethasone versus … promote resistance to antimyeloma drugs through upregulation …

… Before the introduction of ‘novel agents’ such as the immunomodulatory drugs thalidomide
and lenalidomide and the proteasome inhibitor bortezomib in the mid dTTT’s, the ST-year …

… dependent cytotoxicity in Doxorubicinresistant, Lenalidomide… -vitro study showed that although
significant anti-myeloma effects … with perifosine against Akt. J Hematol Oncol. 2013;6:18. …

… drugs such as proteasome inhibitors (eg, bortezomib and carfizomib), immunomodulatory
drugs (eg, thalidomide and lenalidomide)… as a potent anti-myeloma agent in vitro and in animal …

… , and it enhances the anti-myeloma activity of bortezomib [34,… with other chemotherapeutic
drugs (dexamethasone; lenalidomide; … with carfilzomib, bortezomib and/or lenalidomide, and …

… anti-myeloma agents. It is still early to assess whether these … evaluated the combination of
perifosine with bortezomib and … and 27% discontinued lenalidomide due to toxicity which was …

… immunomodulatory drugs (IMiD; Thalidomide, Lenalidomide … For example, combination of
rapamycin with perifosine, an … single agent despite having promising anti-myeloma capabilities…